Vitae Pharmaceuticals (VTAE) to Join NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Vitae Pharmaceuticals Announces Addition to the NASDAQ Biotechnology Index
December 14, 2015 4:15 PM ESTFORT WASHINGTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition will become effective prior to the market open on Monday, December 21, 2015. Vitae is also included in the Russell 3000® and 2000® indices.
The NASDAQ Biotechnology... More
